EDWARDS LIFEDRNEDWARDS LIFEDRNEDWARDS LIFEDRN

EDWARDS LIFEDRN

No trades
See on Supercharts

Key facts today

Goldman Sachs raised the price target on Edwards Lifesciences to $81 from $80, keeping a Buy rating. Analysts show an average outperform rating, with price targets between $63 and $96.80.
Analyze the impactAnalyze the impact
Market capitalization
‪236.14 B‬BRL
37.94BRL
‪6.82 B‬BRL
‪29.19 B‬BRL
‪591.62 M‬
Beta (1Y)
0.48

About Edwards Lifesciences Corporation


CEO
Bernard J. Zovighian
Headquarters
Irvine
Founded
1958
ISIN
BRE1WLBDR000
FIGI
BBG00RD62B78
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.